Beyond Air (NASDAQ:XAIR – Get Free Report) is projected to post its Q2 2027 results after the market closes on Wednesday, November 11th. Analysts expect the company to post earnings of ($3.31) per share and revenue of $2.16 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2027 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.
Beyond Air (NASDAQ:XAIR – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($11.00) EPS for the quarter, missing the consensus estimate of ($10.80) by ($0.20). Beyond Air had a negative return on equity of 440.26% and a negative net margin of 435.71%. The firm had revenue of $1.77 million for the quarter, compared to the consensus estimate of $1.93 million.
Beyond Air Stock Performance
NASDAQ:XAIR opened at $2.32 on Wednesday. Beyond Air has a 52 week low of $2.05 and a 52 week high of $53.20. The company has a debt-to-equity ratio of 7.81, a current ratio of 3.31 and a quick ratio of 3.12. The firm has a 50 day moving average of $2.93 and a 200 day moving average of $10.39.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on XAIR shares. Weiss Ratings raised Beyond Air from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. Lake Street Capital initiated coverage on Beyond Air in a research report on Tuesday, September 1st. They issued a “buy” rating and a $10.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Beyond Air currently has a consensus rating of “Moderate Buy” and an average price target of $105.00.
View Our Latest Analysis on XAIR
About Beyond Air
Beyond Air, Inc is a medical technology and biopharmaceutical company focused on developing nitric oxide (NO) therapies and delivery systems for respiratory diseases and other serious medical conditions. Its platform is designed to generate NO from ambient air at the point of care, potentially reducing reliance on traditional high-pressure gas cylinders.
The company’s primary product family is LungFit, a series of compact NO delivery systems intended for use in hospital and clinical settings.
See Also
- Five stocks we like better than Beyond Air
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
